Advanced Filters
noise

Follicular Lymphoma Clinical Trials

A listing of Follicular Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 318 clinical trials
V Vanderson Rocha

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

The goal of this prospective, multicentric, single-arm, phase I/II clinical trial is to evaluate the safety and efficacy of a novel CD19-directed CAR-T cell locally produced in an academic institution in Brazil in patients with refractory or relapsed acute lymphoblastic leukemia or non-Hodgkin lymphoma. Participants will receive a single intravenous …

3 - 70 years of age All Phase 1/2

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Background Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective To …

18 years of age All Phase 2
A Anna Keryan

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas.

18 years of age All Phase 2
S Silviya Meletath

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

This study is being done to determine the safety, efficacy and tolerability of a single 50 mCi dose of 131I-Apamistamab given prior to CAR-T cell infusion in patients with Relapsed or refractory (R/R) Diffuse large B-cell lymphoma (DLBCL).

18 years of age All Phase 1/2
H He Huang, Doctor

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

A Study of CD 70 CAR T for patients with CD70 positive malignant hematologic diseases

years of age All Phase N/A
R Roman Shapiro, MD

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is …

16 - 75 years of age All Phase 1/2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ …

18 years of age All Phase 2
J JIA WEI

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

The is a multicenter, single arm, open label clinical study on the novel CAR-T combined expression of IL-15 in the treatment of malignant hematological tumors.Plan to recruit 45 subjects with malignant hematological tumors.

years of age All Phase N/A
S Site Public Contact

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

18 years of age All Phase 1

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

This is a multicenter, open label, nonrandomized, sequential dose escalation/cohort expansion, multiple dose study designed to evaluate the safety, toxicity, and PK as well as preliminary efficacy of BTX-A51 in subjects with advanced solid tumors and breast cancer. The study will be done in two phases, described below. Phase 1a …

18 years of age All Phase 1

Simplify language using AI